Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

MKL-PHARMA : revenue, balance sheet and financial ratios

MKL-PHARMA is a French company founded 7 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in LE LOROUX-BOTTEREAU (44430), this company of category PME shows in 2025 a net income positive of 21 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - MKL-PHARMA (SIREN 841003296)
Indicator 2025 2024
Revenue N/C N/C
Net income 21 499 € 20 168 €
EBITDA N/C N/C
Net margin N/C N/C

Revenue and income statement

In 2025, MKL-PHARMA generates positive net income of 21 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2024-2025: 20 k€ -> 21 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

21 499 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 192%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 34%. The balance between equity and debt is satisfactory.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

191.532%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

34.167%

Solvency indicators evolution
MKL-PHARMA

Sector positioning

Debt ratio
191.53 2025
2024
2025
Q1: 0.14
Med: 27.24
Q3: 146.28
Average

In 2025, the debt ratio of MKL-PHARMA (191.53) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
34.17% 2025
2024
2025
Q1: 17.38%
Med: 54.75%
Q3: 87.41%
Average -9 pts over 2 years

In 2025, the financial autonomy of MKL-PHARMA (34.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 6357.66. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

6357.656

Liquidity indicators evolution
MKL-PHARMA

Sector positioning

Liquidity ratio
6357.66 2025
2024
2025
Q1: 159.67
Med: 1116.63
Q3: 6512.12
Good

In 2025, the liquidity ratio of MKL-PHARMA (6357.66) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Positioning of MKL-PHARMA in its sector

Comparison with sector Fonds de placement et entités financières similaires

Valuation estimate

Based on 170 transactions of similar company sales (all years), the value of MKL-PHARMA is estimated at 222 875 € (range 138 150€ - 346 642€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
170 transactions
138k€ 222k€ 346k€
222 875 € Range: 138 150€ - 346 642€
NAF 5 all-time

Valuation method used

Net Income Multiple
21 499 € × 10.4x = 222 876 €
Range: 138 151€ - 346 642€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 170 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fonds de placement et entités financières similaires)

Compare MKL-PHARMA with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about MKL-PHARMA

What is the revenue of MKL-PHARMA ?

The revenue of MKL-PHARMA is not publicly disclosed (confidential accounts filed with INPI).

Is MKL-PHARMA profitable?

Yes, MKL-PHARMA generated a net profit of 21 k€ in 2025.

Where is the headquarters of MKL-PHARMA ?

The headquarters of MKL-PHARMA is located in LE LOROUX-BOTTEREAU (44430), in the department Loire-Atlantique.

Where to find the tax return of MKL-PHARMA ?

The tax return of MKL-PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does MKL-PHARMA operate?

MKL-PHARMA operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.